Key Financial Figures (FY 2025-26)

  • Revenue from Operations: ₹13,230.62 lakhs (FY 2024-25: ₹3,071.85 lakhs)
  • Other Income: ₹3.26 lakhs (FY 2024-25: ₹1.60 lakhs)
  • Total Expenses: ₹12,893.45 lakhs (FY 2024-25: ₹3,061.11 lakhs)
  • Profit Before Tax: ₹340.43 lakhs (FY 2024-25: ₹12.33 lakhs)
  • Provision for Taxation: ₹84.78 lakhs (FY 2024-25: ₹3.88 lakhs)
  • Profit After Tax: ₹255.66 lakhs (FY 2024-25: ₹8.45 lakhs)
  • Earnings Per Share (Basic): ₹1.21 (FY 2024-25: ₹0.08)
  • Earnings Per Share (Diluted): ₹1.75 (FY 2024-25: ₹0.09)

Share Capital Structure

  • Authorized Share Capital: ₹30,00,00,000 divided into 30,000,000 equity shares of ₹10 each
  • Paid-up Share Capital: ₹28,47,00,000 divided into 2,84,70,000 equity shares of ₹10 each as on report date
  • During FY 2025-26: Company allotted 1,11,35,000 equity shares through preferential allotment
  • After FY closure: Company allotted additional 73,85,000 equity shares till date of report

Annual General Meeting Details

  • 32nd AGM Date: Wednesday, 30th September 2026 at 03:00 P.M.
  • Meeting Mode: Video Conferencing/Other Audio Visual Means (OAVM)
  • Record Date: Thursday, 24th September 2026 to Wednesday, 30th September 2026 (both days inclusive)
  • Business to be transacted:
  • Ordinary Business: Adoption of standalone financial statements and re-appointment of Ms. Sridevi Belide as director
  • Special Business: Appointment of Mr. Gnana Prakash Gattu as Whole-time Director for 5 years (29th August 2026 to 28th August 2031)

Board of Directors & Key Managerial Personnel

Directors as on 31st March 2026:

1. Mr. Venkateshwarlu Pulluru - Whole-time Director (DIN: 02076871)

2. Mr. Janardhan Das Kabra - Non-Executive Independent Director (DIN: 2386627)

3. Mr. Lakshman Samala - Non-Executive Independent Director (DIN: 10783725)

4. Mr. Gattu Gnana Prakash - Non-Executive Non-Independent Director (DIN: 00517921)

5. Ms. Mayuri Baidya - Non-Executive Independent Director (DIN: 11242323)

6. Ms. Sridevi Belide - Non-Executive Non-Independent Director (DIN: 10455373)

Key Managerial Personnel:

  • Company Secretary & Compliance Officer: Ms. Nishita Kalantri
  • CFO: Ms. Bhoomika Choudhary

Director Changes During FY 2025-26

  • Mr. Gattu Gnana Prakash resigned as Non-Executive Independent Director w.e.f. 12/04/2025
  • Mr. Jivamohan Divakar Valluri appointed as Additional Non-Executive Non-Independent Director w.e.f. 12/04/2025
  • Mr. Gattu Gnana Prakash reappointed as Additional Non-Executive Non-Independent Director on 14/08/2025
  • Ms. Mayuri Baidya appointed as Additional Non-Executive Independent Director on 14/08/2025
  • Mr. Jivamohan Divakar Valluri resigned w.e.f. 30/03/2026

Corporate Committees

  • Audit Committee: Mr. Janardhan Das Kabra (Chairman), Ms. Mayuri Baidya, Ms. Sridevi Belide
  • Nomination & Remuneration Committee: Mr. Janardhan Das Kabra (Chairman), Ms. Mayuri Baidya, Ms. Sridevi Belide
  • Stakeholder Relationship Committee: Ms. Sridevi Belide (Chairperson), Ms. Mayuri Baidya, Mr. Janardhan Das Kabra

Auditor Appointments

  • Statutory Auditors: M/s CVS Balachandra Rao & Co., Chartered Accountants (FRN: 007507S) appointed until conclusion of 34th AGM
  • Secretarial Auditor: M/s Khushbu Kanwar & Co., Company Secretaries appointed for 5 years till 31st March 2030
  • Internal Auditor: M/s V R P S & Co., Chartered Accountants for FY 2025-26, reappointed for FY 2026-27

Financial Position as at 31st March 2026

Assets:

  • Non-Current Assets: ₹351.20 lakhs (Property, Plant & Equipment: ₹152.18 lakhs, Intangible Assets: ₹192.00 lakhs)
  • Current Assets: ₹8,891.12 lakhs (Inventories: ₹1,443.22 lakhs, Trade Receivables: ₹5,896.15 lakhs, Cash & Cash Equivalents: ₹295.86 lakhs)
  • Total Assets: ₹9,242.32 lakhs

Liabilities & Equity:

  • Equity: ₹4,648.84 lakhs (Share Capital: ₹2,108.50 lakhs, Other Equity: ₹2,540.34 lakhs)
  • Current Liabilities: ₹4,593.48 lakhs (Trade Payables: ₹4,025.37 lakhs)
  • Total Liabilities & Equity: ₹9,242.32 lakhs

Business Operations & Strategy

  • Company has transitioned to pharmaceutical sector focusing on pharmaceutical bulk drugs (APIs) and key starting materials/intermediates
  • Strategic focus on research and development, quality systems, and operational capabilities
  • Building presence in Hyderabad/Telangana pharmaceutical ecosystem
  • Exploring opportunities in domestic and international markets

Dividend & Reserves

  • No dividend recommended for FY 2025-26
  • Surplus to be used for increased working capital needs
  • No amount transferred to reserves

Compliance & Regulatory Aspects

  • Company complied with Secretarial Standards on Board and Annual General Meetings
  • No deposits accepted from public during the year
  • No material changes and commitments during the year
  • No proceedings under Insolvency and Bankruptcy Code, 2016

Auditor Reports

  • Statutory Auditor Report: Unmodified opinion without any qualifications, reservations or adverse remarks
  • Secretarial Auditor Report: Clean report with no qualifications or adverse remarks
  • Internal Financial Controls: Adequate and operating effectively as per auditor report

Other Significant Disclosures

  • Employee Strength: 32 permanent employees as on 31st March 2026
  • Median Employee Remuneration: ₹2,10,000
  • CSR Provisions: Not applicable to the company
  • Related Party Transactions: Disclosed in financial statements, all at arm's length
  • Vigil Mechanism: Whistle Blower Policy in place
  • Sexual Harassment Complaints: No complaints received during the year

E-voting & AGM Participation Details

  • Remote e-voting period: 27th September 2026 (09:00 A.M.) to 29th September 2026 (05:00 P.M.)
  • CDSL appointed as e-voting agency
  • Physical shareholders required to update PAN, KYC details
  • Members can join AGM through VC/OAVM 15 minutes before scheduled time